ArticleCell death discovery2026
RBM14 drives prostate cancer metastasis via stabilizing HK2 mRNA to activate glycolysis and H3K18 lactylation.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Metastasis is a leading cause of poor prognosis in prostate cancer (PCa), yet its underlying regulatory mechanisms remain incompletely understood. Following the establishment of highly invasive PC-3M cell lines, RBM14 expression was found to be significantly elevated in highly invasive cells. Furthermore, RBM14 was upregulated in PCa tissues and positively correlated with adverse clinicopathological features. Functional assays demonstrated that RBM14 significantly promoted PCa cell metastasis in vitro and in vivo. Mechanistically, RBM14 bound HK2 mRNA via its RRM1/2 domains to enhance HK2 stability, thereby upregulating HK2 expression. This increased HK2 level boosted PCa cells' glycolytic capacity, which in turn led to increased global lactylation, especially in histone H3 lysine 18 lactylation (H3K18la). The elevated H3K18la preferentially enriched at the promoters of metastasis-related genes, further upregulating their expression. Importantly, combining RBM14 knockdown with 2-DG exerted a synergistic inhibitory effect on PCa metastasis. Collectively, this study identifies RBM14 as a key regulator of PCa metastasis via the HK2-glycolysis-H3K18la axis, providing a potential therapeutic target for combating PCa metastasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.